Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
7
×
Tags
abbvie
7
×
biotech
boston blog main
boulder/denver blog main
boulder/denver top stories
clinical trials
7
×
detroit blog main
detroit top stories
indiana blog main
indiana top stories
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
7
×
boston top stories
fda
cancer
cancer immunotherapy
eli lilly
startups
astrazeneca
biogen
bristol-myers squibb
glaxosmithkline
nonalcoholic steatohepatitis
novartis
What
bio
7
×
roundup
companies
drug
news
biotech
days
fda
nash
week
abbvie’s
acquisitions
ahead
alzheimer’s
announced
annual
approval
approved
assessed
attention
august
biofourmis
biogen’s
biopharmaceutical
black
bucks
busy
cancer
celebrate
ceo
chance
collabs
communities
conference
continue
convo
corner
covid
daniel
day
Language
unset
Current search:
bio
×
photo
×
" wisconsin top stories "
×
" clinical trials "
×
abbvie
×
@xconomy.com
3 years ago
Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More